Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Keytruda® (pembrolizumab) – Expanded indication
February 15, 2018 - The FDA approved Merck’s Keytruda (pembrolizumab), for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
